JP2013507991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507991A5 JP2013507991A5 JP2012536968A JP2012536968A JP2013507991A5 JP 2013507991 A5 JP2013507991 A5 JP 2013507991A5 JP 2012536968 A JP2012536968 A JP 2012536968A JP 2012536968 A JP2012536968 A JP 2012536968A JP 2013507991 A5 JP2013507991 A5 JP 2013507991A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- amino acid
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 38
- 108091000831 antigen binding proteins Proteins 0.000 claims 38
- 125000000539 amino acid group Chemical group 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 238000006467 substitution reaction Methods 0.000 claims 20
- 238000012217 deletion Methods 0.000 claims 19
- 230000037430 deletion Effects 0.000 claims 19
- 238000003780 insertion Methods 0.000 claims 18
- 230000037431 insertion Effects 0.000 claims 18
- 108010065637 Interleukin-23 Proteins 0.000 claims 15
- 102000013264 Interleukin-23 Human genes 0.000 claims 15
- 239000002904 solvent Substances 0.000 claims 6
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000002424 x-ray crystallography Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25498209P | 2009-10-26 | 2009-10-26 | |
| US61/254,982 | 2009-10-26 | ||
| US38128710P | 2010-09-09 | 2010-09-09 | |
| US61/381,287 | 2010-09-09 | ||
| PCT/US2010/054148 WO2011056600A1 (en) | 2009-10-26 | 2010-10-26 | Human il-23 antigen binding proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236268A Division JP2016102122A (ja) | 2009-10-26 | 2015-12-03 | ヒトｉｌ−２３抗原結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507991A JP2013507991A (ja) | 2013-03-07 |
| JP2013507991A5 true JP2013507991A5 (https=) | 2013-12-05 |
| JP5930968B2 JP5930968B2 (ja) | 2016-06-08 |
Family
ID=43413789
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012536968A Active JP5930968B2 (ja) | 2009-10-26 | 2010-10-26 | ヒトｉｌ−２３抗原結合タンパク質 |
| JP2015236268A Pending JP2016102122A (ja) | 2009-10-26 | 2015-12-03 | ヒトｉｌ−２３抗原結合タンパク質 |
| JP2018045121A Pending JP2018117626A (ja) | 2009-10-26 | 2018-03-13 | ヒトｉｌ−２３抗原結合タンパク質 |
| JP2019166277A Active JP7023908B2 (ja) | 2009-10-26 | 2019-09-12 | ヒトｉｌ－２３抗原結合タンパク質 |
| JP2021177428A Active JP7278355B2 (ja) | 2009-10-26 | 2021-10-29 | ヒトｉｌ－２３抗原結合タンパク質 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236268A Pending JP2016102122A (ja) | 2009-10-26 | 2015-12-03 | ヒトｉｌ−２３抗原結合タンパク質 |
| JP2018045121A Pending JP2018117626A (ja) | 2009-10-26 | 2018-03-13 | ヒトｉｌ−２３抗原結合タンパク質 |
| JP2019166277A Active JP7023908B2 (ja) | 2009-10-26 | 2019-09-12 | ヒトｉｌ－２３抗原結合タンパク質 |
| JP2021177428A Active JP7278355B2 (ja) | 2009-10-26 | 2021-10-29 | ヒトｉｌ－２３抗原結合タンパク質 |
Country Status (39)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| BR112013018374A2 (pt) * | 2011-01-25 | 2016-10-11 | Monell Chemical Senses Centre | composições e métodos para fornecer ou modular o sabor doce e métodos para rastrear os mesmos |
| EP2583979B1 (en) * | 2011-10-19 | 2015-12-16 | Effimune | Methods to prepare antibodies directed against p19 subunit of human IL-23 |
| PL3326649T3 (pl) * | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| SG11201507483PA (en) * | 2013-03-15 | 2015-10-29 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| SG11201507482UA (en) * | 2013-03-15 | 2015-10-29 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| JP2017513854A (ja) | 2014-04-15 | 2017-06-01 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｗｉｓｐ１に結合する抗原結合タンパク質 |
| US10695406B2 (en) | 2014-05-27 | 2020-06-30 | The University Of Queensland | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent |
| AU2015289874A1 (en) | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| EA202193002A2 (ru) | 2014-09-03 | 2022-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23a и фно-альфа, и его применение |
| AU2016215535B2 (en) | 2015-02-04 | 2021-09-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| US11220541B2 (en) | 2015-12-22 | 2022-01-11 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| WO2019023812A1 (en) * | 2017-08-04 | 2019-02-07 | The Hospital For Sick Children | VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF |
| WO2019023811A1 (en) * | 2017-08-04 | 2019-02-07 | The Hospital For Sick Children | NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY |
| TWI744617B (zh) | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| CN112689643A (zh) * | 2018-07-13 | 2021-04-20 | 阿斯特捷利康合作创业有限责任公司 | 用布雷库单抗治疗溃疡性结肠炎 |
| GB201820687D0 (en) * | 2018-12-19 | 2019-01-30 | Kymab Ltd | Antagonists |
| MA56124A (fr) * | 2019-06-04 | 2022-04-13 | Janssen Biotech Inc | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
| CN120441704A (zh) | 2019-06-26 | 2025-08-08 | 圆祥生技股份有限公司 | T细胞活化抗体 |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| JP7758672B2 (ja) | 2019-12-20 | 2025-10-22 | ノヴァロック バイオセラピューティクス， リミテッド | 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法 |
| CN111718414B (zh) * | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
| WO2022041390A1 (zh) * | 2020-08-28 | 2022-03-03 | 江苏荃信生物医药股份有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法 |
| TW202428304A (zh) | 2020-09-10 | 2024-07-16 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
| CN114773466B (zh) * | 2020-11-26 | 2023-08-29 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素23及包含其的试剂盒及其检测方法 |
| US20220373539A1 (en) * | 2021-05-24 | 2022-11-24 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| JP2024526201A (ja) * | 2021-06-25 | 2024-07-17 | サンガモ セラピューティクス，インコーポレイテッド | Ｉｌ－２３ｒに特異的な抗原結合体及びその使用 |
| WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| CN114994331B (zh) * | 2022-05-17 | 2023-02-24 | 无锡科金生物科技有限公司 | 一种检测蛋白表达水平的试剂盒及其制备方法和应用 |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| WO2026060205A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5780597A (en) | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
| CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
| EP0613495B1 (en) | 1991-11-14 | 2005-02-02 | WEISSMANN, Charles | Transgenic non-human animals lacking prion proteins |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| CN100374159C (zh) * | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
| DE69942607D1 (de) | 1998-04-14 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| AU780163B2 (en) | 1999-09-09 | 2005-03-03 | Merck Sharp & Dohme Corp. | Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| WO2004042009A2 (en) | 2002-10-30 | 2004-05-21 | Genentech, Inc. | Inhibition of il-17 production |
| WO2004058178A2 (en) | 2002-12-23 | 2004-07-15 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| US7282204B2 (en) | 2003-03-10 | 2007-10-16 | Schering Corporation | Uses of IL-23 agonists and antagonists; related reagents |
| CN101052726A (zh) | 2003-05-09 | 2007-10-10 | 森托科尔公司 | IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途 |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| US7820168B2 (en) | 2004-12-20 | 2010-10-26 | Schering Corporation | Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17 |
| MY157915A (en) | 2004-12-21 | 2016-08-15 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses. |
| SI2452694T1 (sl) * | 2005-06-30 | 2019-05-31 | Janssen Biotech, Inc. | Protitelesa proti-IL-23, sestavki in postopki uporabe |
| CN103145842A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| DE602006015830D1 (de) | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| PT1931710T (pt) | 2005-08-31 | 2017-03-28 | Merck Sharp & Dohme | Anticorpos anti-il-23 manipulados |
| CN1955248B (zh) | 2005-10-28 | 2011-10-12 | 安集微电子（上海）有限公司 | 钽阻挡层用化学机械抛光浆料 |
| CN101389769A (zh) | 2005-12-28 | 2009-03-18 | 森托科尔公司 | 用于评价和治疗银屑病及相关疾病的标记与方法 |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| KR20090100461A (ko) * | 2007-01-16 | 2009-09-23 | 아보트 러보러터리즈 | 건선의 치료방법 |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
| JP2010518858A (ja) * | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | 操作された抗−ｉｌ−２３ｐ１９抗体 |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| WO2009117289A2 (en) | 2008-03-18 | 2009-09-24 | Abbott Laboratories | Methods for treating psoriasis |
| KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-ｉｌ-12/ｉｌ-23 항체 |
| EP2331078B1 (en) | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US20120128689A1 (en) | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010115092A2 (en) | 2009-04-02 | 2010-10-07 | The Johns Hopkins University | Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer |
| US20120264917A1 (en) | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| SG179135A1 (en) | 2009-09-14 | 2012-05-30 | Abbott Lab | Methods for treating psoriasis |
| JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PH12012501364A1 (en) | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| JP2013520426A (ja) | 2010-02-18 | 2013-06-06 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質 |
| WO2012009760A1 (en) | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| CN103813804A (zh) | 2010-10-06 | 2014-05-21 | Abbvie公司 | 用于治疗银屑病的方法 |
| CN103154031A (zh) | 2010-10-08 | 2013-06-12 | 诺华有限公司 | 利用il-17拮抗剂治疗牛皮癣的方法 |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| TW201242976A (en) | 2011-01-07 | 2012-11-01 | Abbott Lab | Anti-IL-12/IL-23 antibodies and uses thereof |
| SG11201507483PA (en) | 2013-03-15 | 2015-10-29 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| US11220541B2 (en) | 2015-12-22 | 2022-01-11 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| CN112689643A (zh) | 2018-07-13 | 2021-04-20 | 阿斯特捷利康合作创业有限责任公司 | 用布雷库单抗治疗溃疡性结肠炎 |
| US20210079086A1 (en) | 2019-08-21 | 2021-03-18 | Astrazeneca Collaboration Ventures, Llc | Use of Brazikumab to Treat Crohn's Disease |
-
2010
- 2010-10-18 JO JOP/2010/0356A patent/JO3244B1/ar active
- 2010-10-26 PH PH1/2012/500771A patent/PH12012500771A1/en unknown
- 2010-10-26 US US13/504,449 patent/US8722033B2/en active Active
- 2010-10-26 CN CN201510065612.3A patent/CN104761642A/zh active Pending
- 2010-10-26 ES ES10774095.3T patent/ES2613236T3/es active Active
- 2010-10-26 NZ NZ599875A patent/NZ599875A/en not_active IP Right Cessation
- 2010-10-26 PL PL10774095T patent/PL2493925T3/pl unknown
- 2010-10-26 UA UAA201206355A patent/UA113609C2/uk unknown
- 2010-10-26 UY UY0001032971A patent/UY32971A/es not_active Application Discontinuation
- 2010-10-26 MX MX2012004868A patent/MX358249B/es active IP Right Grant
- 2010-10-26 CN CN201910176289.5A patent/CN110407936A/zh active Pending
- 2010-10-26 EP EP19202723.3A patent/EP3656790A1/en not_active Withdrawn
- 2010-10-26 BR BR122020002402A patent/BR122020002402B8/pt active IP Right Grant
- 2010-10-26 HR HRP20170037TT patent/HRP20170037T1/hr unknown
- 2010-10-26 JP JP2012536968A patent/JP5930968B2/ja active Active
- 2010-10-26 TW TW099136594A patent/TWI432210B/zh not_active IP Right Cessation
- 2010-10-26 SI SI201031391A patent/SI2493925T1/sl unknown
- 2010-10-26 SG SG10201800682SA patent/SG10201800682SA/en unknown
- 2010-10-26 AR ARP100103927A patent/AR078778A1/es active IP Right Grant
- 2010-10-26 EP EP10774095.3A patent/EP2493925B1/en active Active
- 2010-10-26 SG SG10202103260TA patent/SG10202103260TA/en unknown
- 2010-10-26 SM SM20170069T patent/SMT201700069T1/it unknown
- 2010-10-26 CA CA3030092A patent/CA3030092C/en active Active
- 2010-10-26 CA CA2778112A patent/CA2778112C/en active Active
- 2010-10-26 RS RS20170119A patent/RS55666B1/sr unknown
- 2010-10-26 CN CN201080059062.XA patent/CN102741285B/zh active Active
- 2010-10-26 AU AU2010315557A patent/AU2010315557B2/en not_active Ceased
- 2010-10-26 EP EP16199576.6A patent/EP3181586A1/en not_active Withdrawn
- 2010-10-26 PE PE2016002001A patent/PE20161327A1/es not_active Application Discontinuation
- 2010-10-26 WO PCT/US2010/054148 patent/WO2011056600A1/en not_active Ceased
- 2010-10-26 KR KR1020147012130A patent/KR101652609B1/ko not_active Expired - Fee Related
- 2010-10-26 EA EA201270571A patent/EA025366B1/ru unknown
- 2010-10-26 PT PT107740953T patent/PT2493925T/pt unknown
- 2010-10-26 NZ NZ625630A patent/NZ625630A/en not_active IP Right Cessation
- 2010-10-26 PE PE2012000564A patent/PE20121579A1/es active IP Right Grant
- 2010-10-26 TW TW103103013A patent/TW201417830A/zh unknown
- 2010-10-26 MY MYPI2012001807A patent/MY156286A/en unknown
- 2010-10-26 LT LTEP10774095.3T patent/LT2493925T/lt unknown
- 2010-10-26 KR KR1020127013696A patent/KR101568461B1/ko not_active Expired - Fee Related
- 2010-10-26 KR KR1020167022998A patent/KR20160118278A/ko not_active Ceased
- 2010-10-26 BR BR112012009854A patent/BR112012009854B8/pt not_active IP Right Cessation
- 2010-10-26 HU HUE10774095A patent/HUE030871T2/en unknown
-
2012
- 2012-04-10 TN TNP2012000167A patent/TN2012000167A1/en unknown
- 2012-04-17 IL IL219241A patent/IL219241A/en active IP Right Grant
- 2012-04-25 ZA ZA2012/03058A patent/ZA201203058B/en unknown
- 2012-04-26 CR CR20120210A patent/CR20120210A/es unknown
- 2012-04-26 CL CL2012001096A patent/CL2012001096A1/es unknown
- 2012-04-26 CO CO12068924A patent/CO6531481A2/es unknown
- 2012-05-18 MA MA34877A patent/MA33757B1/fr unknown
-
2014
- 2014-03-28 US US14/228,556 patent/US9487580B2/en active Active
-
2015
- 2015-12-03 JP JP2015236268A patent/JP2016102122A/ja active Pending
-
2016
- 2016-01-06 HK HK16100056.3A patent/HK1212357A1/xx unknown
- 2016-03-28 IL IL244801A patent/IL244801B/en active IP Right Grant
- 2016-09-21 US US15/271,315 patent/US9951129B2/en active Active
-
2017
- 2017-01-24 CY CY20171100096T patent/CY1118576T1/el unknown
-
2018
- 2018-03-13 JP JP2018045121A patent/JP2018117626A/ja active Pending
- 2018-11-19 US US16/194,896 patent/US20190071498A1/en not_active Abandoned
-
2019
- 2019-06-26 US US16/453,482 patent/US20190322737A1/en not_active Abandoned
- 2019-09-12 JP JP2019166277A patent/JP7023908B2/ja active Active
-
2020
- 2020-02-18 US US16/793,610 patent/US20200181255A1/en not_active Abandoned
- 2020-05-24 IL IL274871A patent/IL274871A/en unknown
- 2020-10-01 US US17/060,905 patent/US20210024626A1/en not_active Abandoned
-
2021
- 2021-04-13 US US17/229,607 patent/US20210230267A1/en not_active Abandoned
- 2021-10-29 JP JP2021177428A patent/JP7278355B2/ja active Active
- 2021-11-12 US US17/525,421 patent/US12012449B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507991A5 (https=) | ||
| MX2025004236A (es) | Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana) | |
| JP2012504955A5 (https=) | ||
| JP2015508762A5 (https=) | ||
| JP2025036561A5 (https=) | ||
| JP2013520996A5 (https=) | ||
| JP2014524748A5 (https=) | ||
| JP2020508303A5 (https=) | ||
| JP2018505177A5 (https=) | ||
| JP2016063812A5 (https=) | ||
| JP2017528476A5 (https=) | ||
| JP2015522252A5 (https=) | ||
| JP2016522168A5 (https=) | ||
| JP2020536888A5 (https=) | ||
| JP2011514150A5 (https=) | ||
| JP2009511480A5 (https=) | ||
| JP2012513214A5 (https=) | ||
| JP2018527952A5 (https=) | ||
| JP2011518125A5 (https=) | ||
| JP2012510461A5 (https=) | ||
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP2011528902A5 (https=) | ||
| JP2012512641A5 (https=) | ||
| HRP20250666T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| HRP20150965T1 (hr) | Anti-fgr3 protutijela i metode koje ih koriste |